RNA therapy
targeted.
RNATICS received €2.7 million for the clinical development of RCS-21
RNATICS GmbH, a spin-off of the Technical University of Munich, was awarded €2.7 million in funding by the Federal Ministry of Research, Technology and Space (BMFTR). The grant will support the clinical development of RCS-21, an inhaled RNA therapeutic candidate that is the first of its kind for treating inflammatory and fibrotic lung diseases.
Vision
To exploit our unique delivery technology targeted to tissue macrophages for the development of a new class of RNA therapeutics.
Aim
RNATICS develops RNA therapeutics directed at disease-causing RNAs in tissue resident macrophages. These immune cells are increasingly recognized as a key cell population in a rapidly increasing number of hard-to-treat severe diseases. Our proprietary targeting technology via carbohydrate-coupling allows efficient delivery of our RNA therapeutics to tissue macrophages and modulate their disease-causing activity. This novel delivery pathway enables access to organs previously not accessible to RNA therapeutics offering tremendous therapeutic opportunities for multiple diseases.
Most advanced towards clinical application is our lung program that targets pulmonary macrophages to treat acute exacerbations in patients suffering from Idiopathic Pulmonary Fibrosis (IPF). The first-in-human study is currently ongoing.
